Search Results - "Menzies, A."

Long‐term corticosteroid use, adrenal insufficiency and the need for steroid‐sparing treatment in adult severe asthma by Gurnell, M., Heaney, L. G., Price, D., Menzies‐Gow, A.

“…Secondary adrenal insufficiency (AI) occurs as the result of any process that disrupts normal hypothalamic and/or anterior pituitary function and causes a…”
Get full text

Novel adjuvant options for cutaneous melanoma by Dimitriou, F., Long, G.V., Menzies, A.M.

“…Patients with resected stage III and IV melanoma have a high risk of recurrence. As the outcomes for patients with metastatic disease have improved…”
Get full text

Nowcasting by Bayesian Smoothing: A flexible, generalizable model for real-time epidemic tracking by McGough, Sarah F, Johansson, Michael A, Lipsitch, Marc, Menzies, Nicolas A

“…Achieving accurate, real-time estimates of disease activity is challenged by delays in case reporting. "Nowcast" approaches attempt to estimate the complete…”
Get full text

Immunotherapy use outside clinical trial populations: never say never? by Rzeniewicz, K., Larkin, J., Menzies, A.M., Turajlic, S.

“…Based on favourable outcomes in clinical trials, immune checkpoint inhibitors (ICIs), most notably programmed cell death protein 1 (PD-1) and cytotoxic…”
Get full text

Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma by Pollack, M.H., Betof, A., Dearden, H., Rapazzo, K., Valentine, I., Brohl, A.S., Ancell, K.K., Long, G.V., Menzies, A.M., Eroglu, Z., Johnson, D.B., Shoushtari, A.N.

“…Combined cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1) blockade induces high rates of immune-related adverse events (irAEs). The…”
Get full text

Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy by Haanen, J., Ernstoff, M.S., Wang, Y., Menzies, A.M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J.A., Obeid, M.

“…Patients with cancer and with preexisting active autoimmune diseases (ADs) have been excluded from immunotherapy clinical trials because of concerns for high…”
Get full text

An Efficient Estimator for the Expected Value of Sample Information by Menzies, Nicolas A.

“…Background. Conventional estimators for the expected value of sample information (EVSI) are computationally expensive or limited to specific analytic…”
Get full text

PET imaging for cancer immunotherapy: the Immuno-PET by Menzies, A.M., Lastoria, S.

Get full text

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma by Lee, J.H., Long, G.V., Boyd, S., Lo, S., Menzies, A.M., Tembe, V., Guminski, A., Jakrot, V., Scolyer, R.A., Mann, G.J., Kefford, R.F., Carlino, M.S., Rizos, H.

“…Programmed death 1 (PD1) inhibitors are now a foundation of medical management of metastatic melanoma. This study sought to determine whether circulating…”
Get full text

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab by Menzies, A.M., Johnson, D.B., Ramanujam, S., Atkinson, V.G., Wong, A.N.M., Park, J.J., McQuade, J.L., Shoushtari, A.N., Tsai, K.K., Eroglu, Z., Klein, O., Hassel, J.C., Sosman, J.A., Guminski, A., Sullivan, R.J., Ribas, A., Carlino, M.S., Davies, M.A., Sandhu, S.K., Long, G.V.

“…Anti-PD-1 antibodies (anti-PD-1) have clinical activity in a number of malignancies. All clinical trials have excluded patients with significant preexisting…”
Get full text

Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma by Fraterman, Itske, Reijers, Irene L. M., Dimitriadis, Petros, Broeks, Annegien, Gonzalez, M., Menzies, A. M. M., Lopez-Yurda, Marta, Kapiteijn, Ellen, van der Veldt, Astrid A. M., Suijkerbuijk, Karijn P. M., Hospers, Geke A. P., Long, Georgina V., Blank, Christian U., van de Poll-Franse, Lonneke V.

“…Neoadjuvant immune checkpoint blockade (ICB) outperforms adjuvant ICB for treatment of stage IIIB–D melanoma, but potential biomarkers of response, such as…”
Get full text

Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation by Menzies, Nicolas A, Cohen, Ted, Lin, Hsien-Ho, Murray, Megan, Salomon, Joshua A

“…The Xpert MTB/RIF test enables rapid detection of tuberculosis (TB) and rifampicin resistance. The World Health Organization recommends Xpert for initial…”
Get full text

FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma by Tan, A.C., Emmett, L., Lo, S., Liu, V., Kapoor, R., Carlino, M.S., Guminski, A.D., Long, G.V., Menzies, A.M.

“…Immune checkpoint inhibitor therapy has resulted in impressive and durable clinical activity for many cancers including melanoma; however, there remain few…”
Get full text

The current and future role of biomarkers in type 2 cytokine‐mediated asthma management by Pavord, I. D., Afzalnia, S., Menzies‐Gow, A., Heaney, L. G.

“…Summary Assessment and management of asthma is complicated by the heterogeneous pathophysiological mechanisms that underlie its clinical presentation, which…”
Get full text

Ongoing partial response at 6 months to olaparib for metastatic melanoma with somatic PALB2 mutation after failure of immunotherapy: a case report by Lau, B., Menzies, A.M., Joshua, A.M.

Get full text

Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy by Owen, C.N., Shoushtari, A.N., Chauhan, D., Palmieri, D.J., Lee, B., Rohaan, M.W., Mangana, J., Atkinson, V., Zaman, F., Young, A., Hoeller, C., Hersey, P., Dummer, R., Khattak, M.A., Millward, M., Patel, S.P., Haydon, A., Johnson, D.B., Lo, S., Blank, C.U., Sandhu, S., Carlino, M.S., Larkin, J.M.G., Menzies, A.M., Long, G.V.

“…Anti-programmed cell death protein 1 (PD-1) antibodies (PD1) prolong recurrence-free survival in high-risk resected melanoma; however, approximately 25%–30% of…”
Get full text

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma by Jansen, Y.J.L., Rozeman, E.A., Mason, R., Goldinger, S.M., Geukes Foppen, M.H., Hoejberg, L., Schmidt, H., van Thienen, J.V., Haanen, J.B.A.G., Tiainen, L., Svane, I.M., Mäkelä, S., Seremet, T., Arance, A., Dummer, R., Bastholt, L., Nyakas, M., Straume, O., Menzies, A.M., Long, G.V., Atkinson, V., Blank, C.U., Neyns, B.

“…Programmed cell death protein 1 (PD-1) blocking monoclonal antibodies improve the overall survival of patients with advanced melanoma but the optimal duration…”
Get full text

The evolution of calcite-bearing kimberlites by melt-rock reaction: evidence from polymineralic inclusions within clinopyroxene and garnet megacrysts from Lac de Gras kimberlites, Canada by Bussweiler, Y., Stone, R. S., Pearson, D. G., Luth, R. W., Stachel, T., Kjarsgaard, B. A., Menzies, A.

“…Megacrystic (>1 cm) clinopyroxene (Cr-diopside) and garnet (Cr-pyrope) xenocrysts within kimberlites from Lac de Gras (Northwest Territories, Canada) contain…”
Get full text

A novel post-developmental role of the Hox genes underlies normal adult behavior by Raouf Issa, A, A C Menzies, Jonathan, Padmanabhan, Aishwarya, Alonso, Claudio R

“…The molecular mechanisms underlying the stability of mature neurons and neural circuits are poorly understood. Here we explore this problem and discover that…”
Get full text

The potential impact of novel tuberculosis vaccine introduction on economic growth in low- and middle-income countries: A modeling study by Portnoy, Allison, Arcand, Jean-Louis, Clark, Rebecca A, Weerasuriya, Chathika K, Mukandavire, Christinah, Bakker, Roel, Patouillard, Edith, Gebreselassie, Nebiat, Zignol, Matteo, Jit, Mark, White, Richard G, Menzies, Nicolas A

“…Most individuals developing tuberculosis (TB) are working age adults living in low- and middle-income countries (LMICs). The resulting disability and death…”
Get full text